Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Unknown 3Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 20Breast 17Genitourinary 7Gastrointestinal 6Thoracic 5Other solid neoplasm 5Sarcoma 4Tumor-Agnostic 1Head & Neck 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2SCLC, Extensive Stage 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × fluzoparib × Thoracic × Clear all
NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
100 enrolled
Thoracic

SCLC, Extensive Stage

NCT04400188 2025-06-29

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
25 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04828395 2021-05-11

F&C

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
65 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04659785 2020-12-09

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer(FA-ES-SCLC)

Tianjin Medical University Second Hospital

Phase 1/2 Unknown
53 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡